This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma

This study has been terminated.
(not enough eligible patients)
Information provided by (Responsible Party):
Louis Constine, University of Rochester Identifier:
First received: May 15, 2009
Last updated: May 24, 2016
Last verified: May 2016
This study is to inquire by mailed survey regarding the cardiac and general health of patients previously treated for Hodgkin's and non-Hodgkin's lymphoma with radiation therapy/anthracycline chemotherapy.

Condition Intervention
Hodgkin Disease Lymphoma, Non-Hodgkin Other: Survey

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma After Radiation Therapy/Anthracycline Chemotherapy

Resource links provided by NLM:

Further study details as provided by Louis Constine, University of Rochester:

Primary Outcome Measures:
  • Measure changes in Cardiac ejection fraction score [ Time Frame: Post Radiation Treatment ]
  • Measure changes in perfusion imaging score on the radionuclide cardiac profusion scan [ Time Frame: Post Radiation ]

Enrollment: 32
Study Start Date: August 2008
Estimated Study Completion Date: November 2017
Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Individuals who have previously received radiation therapy and anthracycline chemotherapy for their Hodgkin's or non-Hodgkin's lymphoma.
Other: Survey
Survey asking questions regarding the subjects cardiac and general health.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients previously treated at the University of Rochester Department of Radiation Oncology.

Inclusion Criteria:

  • All patients with Hodgkin's Lymphoma and Non Hodgkin's lymphoma who underwent Radiation Therapy (RT) to either a mantle or modified mantle field with or without adriamycin at the Wilmot Cancer Center at the University of Rochester are eligible for the study.

Exclusion Criteria:

  • Any severe preexisting cardiac disease (e.g., arrhythmia, angina, coronary disease, myocardial infarction, or congestive heart failure) prior to diagnosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00903890

United States, New York
University of Rochester Medical Center
Rochester, New York, United States, 14642
Sponsors and Collaborators
University of Rochester
Principal Investigator: Louis S Constine, MD University of Rochester
  More Information

Responsible Party: Louis Constine, Professor, University of Rochester Identifier: NCT00903890     History of Changes
Other Study ID Numbers: ULYM07056
Study First Received: May 15, 2009
Last Updated: May 24, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Hodgkin Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on September 25, 2017